home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

Engineered Molecule Selectively Kills Specific T-cell Populations

 
  February, 7 2001 2:24
your information resource in human molecular genetics
 
     
Targeting troublesome T cells

The T cells of the immune system play an important role in defending the body against invading microorganisms. However, sometimes subsets of these cells fail to distinguish friend from foe, wrecking havoc with the body's own tissues and leading to allergies or autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. One strategy for treatment would be to suppress the activity of all T cells, but this can seriously compromise an individual's immunity. Now, Teodor-D Brumeneanu and colleagues have devised a way to selectively eliminate only those T cells that are causing the problem (Nature Biotechnology, Vol. 19, Issue 2, 01 Feb 2001, p. 142-147).

T cells express protein structures (receptors) on their cell surface that permit them to spot and then bind other protein "flags"-called antigens-on a foreign target. Groups of T cells express different receptors that allow them to recognize various intruders. Using a model system that reflects what might occur in the body, the researchers exploited this property by engineering a molecule that could bind to a specific subset of T cells, delivering a toxic drug called doxorubicin to those cells.

In the test tube, the engineered molecule selectively killed the cells. When tested in mice, it also reduced the concentration of the targeted T cells compared with the free drug. Although preliminary, the results suggest that targeted drug of this type could be useful in treating autoimmune diseases by eliminating specific T cell populations.

Contact (author)
Dr. Teodor-D. Brumeanu
Mount Sinai School of Medicine
Department of Microbiology
New York, NY 10029
Tel: 212-241-7551
Fax: 212-828-4151
Email: brumet01@doc.mssm.edu

(C) Nature Biotechnology press release.


Message posted by: Trevor M. D'Souza

print this article mail this article
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2016 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.